Last checked at 12 Dec 2017 10:17
12th December 2017
Physiomics plc
("Physiomics") or ("the Company")
Director Dealing
The Company announces that it received notice today that the following Directors sold the following number of ordinary shares in the Company at the following prices per share:
Director | Number of shares sold | Sale price per share |
Dr J Millen, CEO | 240,000 | 8.3p |
Dr C Chassagnole, COO | 600,000 | 8.3p |
Following the sales of shares, the total holdings of each Director of the Company will be as follows:
Dr Paul Harper 525,707
Dr Jim Millen 444,641
Dr Christophe Chassagnole 417,008
The total number of shares in issue remains 58,785,394 Ordinary Shares with voting rights attached (one vote per Share). There are no Shares held in treasury. This total voting rights figure may be used by shareholders as the denominator for the calculations by which they will determine whether they are required to notify their interests in, or a change to their interest in, Physiomics under the Disclosure and Transparency Rules.
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | James Millen | ||||
2 | Reason for the notification | |||||
a) | Position/status | Director, CEO | ||||
b) | Initial notification/ Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Physiomics plc | ||||
b) | LEI | 213800A71DSZ6ABMTQ91 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary share
GB00BDR6W943 | ||||
b) | Nature of the transaction | Disposal of shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price |
240,000 At 8.3p per share | ||||
e) | Date of the transaction | 12-12-2017 | ||||
f) | Place of the transaction | XLON, AIM | ||||
NOTIFICATION AND PUBLIC DISCLOSURE OF TRANSACTIONS BY PERSONS DISCHARGING MANAGERIAL RESPONSIBILITIES AND PERSONS CLOSELY ASSOCIATED WITH THEM
1 | Details of the person discharging managerial responsibilities/person closely associated | |||||
a) | Name | Christophe Chassagnole | ||||
2 | Reason for the notification | |||||
a) | Position/status | Director, COO | ||||
b) | Initial notification/ Amendment | Initial notification | ||||
3 | Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor | |||||
a) | Name | Physiomics plc | ||||
b) | LEI | 213800A71DSZ6ABMTQ91 | ||||
4 | Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted | |||||
a) | Description of the financial instrument, type of instrument
Identification code | Ordinary share
GB00BDR6W943 | ||||
b) | Nature of the transaction | Disposal of shares | ||||
c) | Price(s) and volume(s) |
| ||||
d) | Aggregated information - Aggregated volume - Price |
600,000 At 8.3p | ||||
e) | Date of the transaction | 12-12-2017 | ||||
f) | Place of the transaction | XLON, AIM | ||||
Enquiries:
Physiomics plc
Dr Jim Millen, CEO
+44 (0)1865 784 980
WH Ireland Limited (nomad)
Katy Mitchell, James Sinclair-Ford
+44 (0) 161 832 2174
Hybridan LLP (broker)
Claire Louise Noyce
+44 (0) 203 764 2341
The information contained within this announcement is deemed by the Company to constitute inside information under the Market Abuse Regulation (EU) No. 596/2014.